2.60Open1.85Pre Close3 Volume5 Open Interest12.50Strike Price780.00Turnover85.97%IV2.10%PremiumDec 20, 2024Expiry Date2.29Intrinsic Value100Multiplier30DDays to Expiry0.31Extrinsic Value100Contract SizeAmericanOptions Type0.7923Delta0.0777Gamma5.24Leverage Ratio-0.0184Theta0.0075Rho4.15Eff Leverage0.0123Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet